Skip to main content

Research Repository

Advanced Search

Browse


FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer (2015)
Journal Article
Jones, D., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget, 6(30), 29782-29794. https://doi.org/10.18632/oncotarget.4927

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression... Read More about FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy (2015)
Journal Article
O'Neill, D., O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., …Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. https://doi.org/10.18632/oncotarget.4347

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection o... Read More about Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer (2014)
Journal Article
Wade, M. A., Jones, D., Wilson, L., Stockley, J., Coffey, K., Robson, C. N., & Gaughan, L. (2015). The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Research, 43(1), 196-207. https://doi.org/10.1093/nar/gku1298

Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in ER co-regulatory protei... Read More about The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.